Chodak on Urology

• Does a High-Veggie Diet a Day Keep Prostate Cancer Progression at Bay?   Dr Chodak discusses phase 3 results from the Men's Eating and Living Study assessing the effects of dietary intervention to prevent disease progression in patients with prostate cancer.
  Medscape Urology, August 03, 2018
• USPSTF Recs on Prostate Cancer Screening: New or Déjà Vu?   The USPSTF's recently updated prostate cancer screening guidelines will challenge physicians to deliver accurate information to patients quickly and easily, argues Dr Gerald Chodak.
  Medscape Urology, July 27, 2018
• Prostate Core Biopsy: Good Predictor of Adverse Pathology?   Don't necessarily discount active surveillance for patients with adverse pathology on prostate core biopsy, says Dr Chodak.
  Medscape Urology, July 16, 2018
• PSA 'Bounce' Probably Not an Adverse Effect of Radiation   Dr Chodak discusses significant findings on the implications of PSA bounce after external beam radiation therapy.
  Medscape Urology, June 06, 2018
• Should MRI Be Standard in Men Without a Previous Prostate Biopsy?   A new study published in the New England Journal of Medicine provides support for doing multiparametric MRI in men with raised PSA levels who have not undergone biopsy, says Dr Gerald Chodak.
  Medscape Urology, April 27, 2018
• One-and-Done PSA Screening?   Is once enough? Dr Chodak reviews a new trial evaluating the effect of one PSA test on prostate cancer-specific mortality.
  Medscape Urology, April 09, 2018
• Apalutamide's Approval for Prostate Cancer Raises New Questions   New research finds that apalutamide is associated with significant improvement in men with nonmetastatic, castration-resistant prostate cancer.
  Medscape Urology, March 15, 2018
• Which Combo for Newly Diagnosed Metastatic Prostate Cancer?   The combination of abiraterone, prednisone, and castration proves to be a beneficial option for metastatic prostate cancer.
  Medscape Urology, March 09, 2018
• Enzalutamide 'Encouraging' in Hormone- Naive Prostate Cancer   Enzalutamide may have a role in prostate cancer therapy, but randomized trials are needed, says Dr Chodak.
  Medscape Urology, February 23, 2018
• Salvage Radiotherapy After Prostatectomy: Who Benefits?   Dr Chodak discusses studies that help elucidate which men may benefit from salvage radiotherapy after prostatectomy.
  Medscape Urology, February 07, 2018
• Recent Reports About HIFU 'Troubling'   Despite new reports of HIFU for focalized therapy of prostate cancer, Dr Chodak remains unconvinced of its evidence.
  Medscape Urology, February 07, 2018
• Testosterone Therapy and PCa Risk in Hypogonadal Men   Dr Chodak reviews a 'provocative' study on the risk for prostate cancer in men receiving testosterone therapy for hypogonadism.
  Medscape Urology, December 27, 2017
• Predicting Prostate Cancer Outcomes With Genomic Testing   Dr Chodak reviews a new study on the 17-gene Genomic Prostate Score used for predicting prostate cancer outcomes.
  Medscape Urology, November 22, 2017
• Men With Prostate Cancer Receive Inadequate Counseling   Research finds that men have poor understanding of treatment outcomes for localized prostate cancer. It's a serious problem, says Dr Chodak.
  Medscape Urology, November 02, 2017
• Analysis of PSA Screening Trials: More Clarity or Confusion?   Does a new analysis of the PLCO and ERSPC trials confirm mortality benefit of PSA screening? Not so fast, says Dr Chodak.
  Medscape Urology, October 13, 2017
• Exercise May Lower Prostate Cancer-Specific Mortality   How much physical activity is enough to reduce prostate cancer mortality? Dr Chodak reviews a new subanalysis of data from the Prostate Cancer Prevention Trial.
  Medscape Urology, October 05, 2017
• Effects of Early and Delayed ADT on Patient QOL   Dr Gerald W. Chodak reviews the latest data from a randomized multicenter trial on the effects of early vs delayed ADT in men with rising PSA after local treatment, or with noncurable de novo disease.
  Medscape Urology, September 22, 2017
• PIVOT: Latest Data on Surveillance Versus Surgery for Prostate Cancer   Dr Gerald Chodak provides his perspective on updated data from a large trial of surveillance versus definitive treatment for prostate cancer, including strengths and weaknesses of the study.
  Medscape Urology, August 30, 2017
• Combo Data Creates New Choices in Metastatic Prostate Cancer   New, more effective antiandrogens are improving outcomes for men with newly diagnosed metastatic prostate cancer. The challenge is in choosing which to use, says Dr Chodak.
  Medscape Urology, August 21, 2017
• New Data Change Metastatic Prostate Cancer Treatment Paradigm   Dr Chodak reviews results of the LATITUDE trial, which compared ADT alone versus ADT with abiraterone acetate plus prednisone.
  Medscape Urology, August 14, 2017